Advanced Search:
Equity Index

ABNX.PA - ABIONYX PHARMA

€1.19  0.102 (9.34%)

Updated: 08:44 May 21, 2024 EST

Next Session's AI Forecast

95.5%

Avg. Accuracy (AI)

€1.02

Next Week's AI Forecast

33.33%

Trend's Accuracy (AI)

€1.18

ABIONYX PHARMA's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

ABIONYX PHARMA - HISTORICAL DATA 6M

  • Last price

    €1.19

  • Daily change

    €0.102

  • Previous Close

    €1.092

  • Last Updated

    08:44 May 21, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-2.01 0.11 -0 -0.07 -0.15

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
3.2 2.33 1.94 1.97 2.03

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
1.72% 38.71% 39.36% 60.42%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
1.09 0% 1.09 0.93% 1.08 -6.9% 1.16

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1 50 2 50

ABIONYX PHARMA Technical Analysis News

ABIONYX PHARMA

33 43 av. Georges Pompidou Bât. D2
Balma 31130
France
33 5 62 24 97 06
https://abionyx.com

Sectors: Healthcare
Industry: Biotechnology
Description

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.

Corporate Governance

ABIONYX Pharma SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.